Gilead's (NASDAQ:GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary objective in a Phase II trial in which, in combination with other drugs, it went up against Stribild, also from Gilead. With TAF achieving a similar virological response to Stribild, the company now plans to undertake further studies. (PR)
Gilead's (NASDAQ:GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary...
Recommended For You
About GILD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GILD | - | - |
Gilead Sciences, Inc. |